Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DTYMK | P23919 | 4/20 | 0.75 |
| ▸ | TERT | O14746 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.54 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.54 |
| ▸ | F2 | P00734 | 1/20 | 0.53 |
| ▸ | TK1 | P04183 | 1/20 | 0.52 |
| ▸ | TYMS | P04818 | 1/20 | 0.52 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29607650 | 1.00 | DTYMK (0.75) | DTYMKTERTPOLBENPP1P2RY1 | |
| SCHEMBL30122220 | 1.00 | DTYMK (0.75) | DTYMKTERTPOLBENPP1P2RY1 | |
| SCHEMBL29362454 | 1.00 | DTYMK (0.75) | DTYMKTERTPOLBENPP1P2RY1 | |
| SCHEMBL17268344 | 0.95 | DTYMK (0.74) | DTYMKTERTPOLBENPP1P2RY1 | |
| SCHEMBL8613042 | 0.95 | DTYMK (0.74) | DTYMKTERTPOLBENPP1P2RY1 | |
| SCHEMBL8612856 | 0.95 | DTYMK (0.74) | DTYMKTERTPOLBENPP1P2RY1 | |
| SCHEMBL16983788 | 0.93 | DTYMK (0.66) | DTYMKTERTPOLBENPP1P2RY1 | |
| SCHEMBL30632043 | 0.93 | DTYMK (0.66) | DTYMKTERTPOLBENPP1P2RY1 | |
| SCHEMBL16979766 | 0.93 | DTYMK (0.66) | DTYMKTERTPOLBENPP1P2RY1 | |
| SCHEMBL9160842 | 0.93 | DTYMK (0.83) | DTYMKTERTPOLBENPP1P2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12247200-B2 | Compositions and methods for generating massively parallel nucleic acid sequencing libraries | BIOO SCIENTIFIC CORPORATION (US) | 2025-03-11 | — | — | US | claimed |
| EP-4061961-B1 | METHOD FOR DOUBLE STRAND SEQUENCING | OXFORD NANOPORE TECH PLC (GB) | 2026-04-08 | — | — | EP | disclosed |
| US-20260085315-A1 | POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | APTAH BIO INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-20260031186-A1 | PRE-END MOTIFS, POST-END MOTIFS, 5-EM, AND 3-EM AND COMBINATIONS FOR ANALYSIS OF CELL-FREE DNA | CENTRE FOR NOVOSTICS (HK) | 2026-01-29 | — | — | US | disclosed |
| US-20260022377-A1 | POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | APTAH BIO INC (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4652278-A1 | POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | Aptah Bio, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4652277-A1 | POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | Aptah Bio, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4100032-B1 | GENE EDITING METHODS FOR TREATING SPINAL MUSCULAR ATROPHY | BROAD INST INC (US) | 2025-10-15 | — | — | EP | disclosed |
| US-20250207189-A1 | DINUCLEOTIDE STOCHASTIC SEQUENCING | 10X GENOMICS, INC. | 2025-06-26 | — | — | US | disclosed |
| CN-120019143-A | Evolved cytidine deaminase and method of editing DNA using the same | 布罗德研究所股份有限公司 | 2025-05-16 | — | — | CN | disclosed |
| EP-4164799-A1 | MOLECULAR ELECTRONIC SENSORS FOR MULTIPLEX GENETIC ANALYSIS USING DNA REPORTER TAGS | Roswell Biotechnologies, Inc. (US) | 2023-04-19 | — | — | EP | disclosed |
| CN-115851666-A | Novel Cas enzymes and systems and uses | 山东舜丰生物科技有限公司 | 2023-03-28 | — | — | CN | disclosed |
| CN-115777025-A | Apparatus and method for genomic structure analysis | 德迈逊科技有限公司 | 2023-03-10 | — | — | CN | disclosed |
| US-20230047776-A1 | POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR GENE EXPRESSION REGULATIONS | APTAH BIO, INC. | 2023-02-16 | — | — | US | disclosed |
| WO-2023288111-A2 | POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR GENE EXPRESSION REGULATION | APTAH BIO, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| EP-4100032-A1 | GENE EDITING METHODS FOR TREATING SPINAL MUSCULAR ATROPHY | The Broad Institute Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| US-20220389481-A1 | METHOD FOR DOUBLE STRAND SEQUENCING | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2022-12-08 | — | — | US | disclosed |
| EP-4061961-A1 | METHOD FOR DOUBLE STRAND SEQUENCING | Oxford Nanopore Technologies PLC (GB) | 2022-09-28 | — | — | EP | disclosed |
| CN-114945679-A | Method for double-strand sequencing | 牛津纳米孔科技公开有限公司 | 2022-08-26 | — | — | CN | disclosed |
| CN-114836571-A | Tomato powdery mildew resistance related KASP molecular marker and application thereof | 北京通州国际种业科技有限公司 | 2022-08-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260031186-A1 | PRE-END MOTIFS, POST-END MOTIFS, 5-EM, AND 3-EM AND COMBINATIONS FOR ANALYSIS OF CELL-FREE DNA | CPSF6, DNMT3A, FEN1 | DTYMK 351/4885TERT 2785/4885POLB 53/4885 |
| US-20260085315-A1 | POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | RPRD2, RTCB, UPF1 | DTYMK 204/4885TERT 723/4885POLB 224/4885 |
| US-20260022377-A1 | POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | PRNP, UPF1, FUS | DTYMK 533/4885TERT 397/4885POLB 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.